MBI 002

Drug Profile

MBI 002

Alternative Names: MBI-002

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Mycenax Biotech
  • Class Antibodies; Antineoplastics
  • Mechanism of Action Checkpoint kinase stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 15 May 2017 Preclinical trials in Solid tumours in Taiwan prior to May 2017 (unspecified route)
  • 15 May 2017 Mycenax announces intention to submit IND to US FDA for Solid tumours in 2019
  • 15 May 2017 MBI-002 is licensed to Mycenax Biotech worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top